Astrocyte Reprogramming via Single Transcription Factor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current direct lineage reprogramming strategies for oligodendrocyte lineage cells (OLCs) in the central nervous system (CNS) lack specificity in generating targeted types of OLCs for different diseases and injuries, as they often rely on combinatorial transcription factor cocktails and do not effectively target astrocytes for in vivo conversion.
Innovation Solution
The method involves using a single transcription factor, such as Olig2, Sox10, or Nkx6.2, linked to an astrocyte-specific promoter, delivered via viral vectors or nanoparticles to convert astrocytes into specific types of oligodendrocyte lineage cells (iOLCs) in vivo, tailored to address specific disease needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If combinatorial transcription factor cocktails are used for direct lineage reprogramming, then reprogramming efficiency is improved, but device complexity and treatment complexity increase
Solution Approach 1:
The patent extracts and identifies the critical transcription factor Olig2 from complex combinatorial cocktails used in prior art. By focusing on this single key factor that is endogenously expressed in oligodendrocytes, the invention simplifies the reprogramming approach while maintaining effectiveness, thereby reducing treatment complexity without sacrificing reprogramming efficiency
Solution Approach 2:
The invention changes the parameter of transcription factor composition from multiple factors (cocktail) to a single critical factor (Olig2). This parameter change simplifies the reprogramming system while achieving the desired cellular conversion, resolving the contradiction between efficiency and complexity
2Manufacturing precision
If astrocyte-specific promoters are used to drive transcription factor expression, then cell-type specificity is improved, but device complexity increases due to promoter design requirements
Solution Approach 1:
The patent applies local quality by using the GFAP promoter, which is specifically active in astrocytes. This promoter ensures that the Olig2 transcription factor is expressed only in the target cell type (astrocytes), providing precise spatial and cellular specificity. The promoter acts as a localized control mechanism that confers cell-type specificity without requiring complex multi-component systems
3Adaptability or versatility
If in vivo reprogramming is performed, then therapeutic applicability is improved, but control precision over reprogramming outcome decreases
Solution Approach 1:
The patent uses viral vectors as intermediaries to deliver the Olig2 transcription factor gene into astrocytes in vivo. These vectors serve as mediators that enable precise control of gene delivery and expression levels in the living organism, while still allowing the reprogramming process to occur naturally within the therapeutic context. This intermediary approach bridges the gap between controlled experimental conditions and complex in vivo therapeutic applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the targeted generation of specific types of iOLCs, such as oligodendrocyte progenitor cells or myelinating oligodendrocytes, enhancing myelination and improving therapeutic outcomes for CNS diseases and injuries by leveraging the unique roles of each transcription factor.
Implementation Method 1
delivered via viral vectors or nanoparticles to convert astrocytes into specific types of oligodendrocyte lineage cells (iOLCs) in vivo
Data Source
AI summary
The present application provides methods for production of induced oligodendrocyte lineage cells (IOLCs) from donor astrocytes comprising contact the donor astrocytes with a polynucleotide comprising a nucleic acid encoding a single transcription factor (TF), wherein the single TF is Olig2, Sox10, or Nkx6.2. Also provided are pharmaceutical compositions for performing the method and associated uses thereof.